It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Peptide hormones and neuropeptides are complex signaling molecules that predominately function through G protein-coupled receptors (GPCRs). Two unanswered questions remaining in the field of peptide-GPCR signaling systems pertain to the basis for the diverse binding modes of peptide ligands and the specificity of G protein coupling. Here, we report the structures of a neuropeptide, galanin, bound to its receptors, GAL1R and GAL2R, in complex with their primary G protein subtypes Gi and Gq, respectively. The structures reveal a unique binding pose of galanin, which almost ‘lays flat’ on the top of the receptor transmembrane domain pocket in an α-helical conformation, and acts as an ‘allosteric-like’ agonist via a distinct signal transduction cascade. The structures also uncover the important features of intracellular loop 2 (ICL2) that mediate specific interactions with Gq, thus determining the selective coupling of Gq to GAL2R. ICL2 replacement in Gi-coupled GAL1R, μOR, 5-HT1AR, and Gs-coupled β2AR and D1R with that of GAL2R promotes Gq coupling of these receptors, highlighting the dominant roles of ICL2 in Gq selectivity. Together our results provide insights into peptide ligand recognition and allosteric activation of galanin receptors and uncover a general structural element for Gq coupling selectivity.
The basis for the diverse peptide-binding modes and the G protein selectivity of peptide GPCRs remains elusive. Here, the authors offer a structural basis for allosteric-like agonism and G protein selectivity of a neuropeptide GPCR, galanin receptor.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (GRID:grid.419093.6) (ISNI:0000 0004 0619 8396); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
2 Zhejiang University School of Medicine, Hangzhou, Department of Biophysics and Department of Pathology of Sir Run Run Shaw Hospital, Zhejiang, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
3 School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China (GRID:grid.410745.3) (ISNI:0000 0004 1765 1045); CAS Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (GRID:grid.410611.3) (ISNI:0000 0004 7699 6713)
4 CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (GRID:grid.419093.6) (ISNI:0000 0004 0619 8396)
5 CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (GRID:grid.419093.6) (ISNI:0000 0004 0619 8396); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); School of Life Science and Technology, ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879)
6 Zhejiang University School of Medicine, Hangzhou, Department of Biophysics and Department of Pathology of Sir Run Run Shaw Hospital, Zhejiang, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); MOE Frontier Science Center for Brain Research and Brain-Machine Integration, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Key Laboratory of Immunity and Inflammatory Diseases of Zhejiang Province, Hangzhou, China (GRID:grid.13402.34)
7 CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (GRID:grid.419093.6) (ISNI:0000 0004 0619 8396); School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China (GRID:grid.410745.3) (ISNI:0000 0004 1765 1045); CAS Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (GRID:grid.410611.3) (ISNI:0000 0004 7699 6713); State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (GRID:grid.419093.6) (ISNI:0000 0004 0619 8396); School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
8 CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (GRID:grid.419093.6) (ISNI:0000 0004 0619 8396); School of Life Science and Technology, ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); Lingang Laboratory, Shanghai, China (GRID:grid.440637.2)